AstraZeneca Plc - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'AstraZeneca Plc - Product Pipeline Review - 2016', provides an overview of the AstraZeneca Plc's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by AstraZeneca Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of AstraZeneca Plc - The report provides overview of AstraZeneca Plc including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses AstraZeneca Plc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features AstraZeneca Plc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to Buy - Evaluate AstraZeneca Plc's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for AstraZeneca Plc - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding AstraZeneca Plc's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 7 AstraZeneca Plc Snapshot 8 AstraZeneca Plc Overview 8 Key Information 8 Key Facts 8 AstraZeneca Plc - Research and Development Overview 9 Key Therapeutic Areas 9 AstraZeneca Plc - Pipeline Review 19 Pipeline Products by Stage of Development 19 Pipeline Products - Monotherapy 20 Pipeline Products - Combination Treatment Modalities 21 Pipeline Products - Partnered Products 22 Pipeline Products - Out-Licensed Products 25 AstraZeneca Plc - Pipeline Products Glance 27 AstraZeneca Plc - Late Stage Pipeline Products 27 AstraZeneca Plc - Clinical Stage Pipeline Products 30 AstraZeneca Plc - Early Stage Pipeline Products 34 AstraZeneca Plc - Drug Profiles 39 (avibactam + ceftazidime) 39 (dapagliflozin propanediol + saxagliptin) 41 (formoterol fumarate + glycopyrrolate) 43 (metformin hydrochloride + saxagliptin) 45 brodalumab 47 cangrelor tetrasodium 49 cediranib maleate 51 ceftaroline fosamil 54 dapagliflozin propanediol 57 osimertinib mesylate 60 propofol 63 ticagrelor 64 (aclidinium bromide + formoterol fumarate) 68 (budesonide + formoterol fumarate + glycopyrrolate) 70 (dapagliflozin propanediol + metformin hydrochloride + saxagliptin) 72 fulvestrant 74 gefitinib 76 glycopyrrolate 81 olaparib 83 omega-3-carboxylic acids 87 PT-009 89 quetiapine fumarate ER 90 roxadustat 91 selumetinib sulfate 94 AZD-3293 98 AZD-4547 99 (avibactam sodium + ceftaroline fosamil) 101 abediterol napadisylate 102 AZD-1775 104 AZD-1981 106 AZD-2014 107 AZD-3241 109 AZD-3759 110 AZD-4017 111 AZD-5363 113 AZD-7594 115 AZD-7624 116 AZD-9150 117 interferon beta-1a 118 lesogaberan 120 PT-008 121 RDEA-3170 122 sapitinib 123 saracatinib difumarate 125 savolitinib 127 Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease 130 AZD-5069 131 AZD-5312 133 (allopurinol + lesinurad) 134 (avibactam sodium + aztreonam lysine) 135 (insulin human + pramlintide acetate) 136 ARC-165395XX 137 AZD-0156 138 AZD-0424 139 AZD-3965 140 AZD-4076 142 AZD-5634 143 AZD-5718 144 AZD-6738 145 AZD-7451 147 AZD-7986 148 AZD-8108 149 AZD-8186 150 AZD-8835 151 AZD-8871 152 AZD-8999 153 AZD-9496 154 AZD-9567 155 dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide 156 LAS-40468 157 MEDI-7352 158 AC-163794 159 ADP-31417 160 ADP-71296 161 AZ-12260493 162 AZ-12441970 163 AZ-12861903 164 AZ-13483342 165 AZ-20 166 AZ-4217 167 AZ-4425 168 AZ-64 169 AZ-709 170 AZ-876 171 AZD-0449 172 AZD-2098 173 AZD-2858 174 AZD-3463 175 AZD-3857 176 AZD-4831 177 AZD-9708 178 CWGNC-41 179 Drug 1 for Cancer 180 Drug 2 for Cancer 181 Drug 3 for Cancer 182 Drug 4 for Cancer 183 Drug 5 for Cancer 184 Drug 6 for Cancer 185 HTL-1071 186 KU-59403 187 LAS-191351 188 LAS-194871 189 LCB-010200 190 MMV-253 191 Monoclonal Antibody Conjugates for Oncology 192 NBTI-5463 193 NKTR-119 194 OX-CLI 195 PL-8905 196 Small Molecule for Malaria 197 Small Molecule for Oncology 198 Small Molecule to Antagonize Histamine 3 Receptor for Cognition 199 Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology 200 Small Molecule to Block Kv1.5 for Atrial Fibrillation 201 Small Molecule to Inhibit DNA Gyrase for Streptococcal Pneumonia 202 Small Molecule to Inhibit PI3K Beta for Bleeding and Clotting Disorders 203 Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia 204 Small Molecules 1 for Malaria 205 Small Molecules for Dyslipidemia and Hypertriglyceridemia 206 Small Molecules to Antagonize GPR103 for Obesity 207 Small Molecules to Antagonize M3 Receptors for Respiratory Disorders 208 Small Molecules to Antagonize P2X3 for Chronic Pain 209 Small Molecules to Inhibit CDK9 for Inflammatory Pain and Rheumatoid Arthritis 210 Small Molecules to Inhibit DNA GyrB for Tuberculosis 211 Small Molecules to Inhibit DprE1 for Tuberculosis 212 Synthetic Peptide for Neuropathic Pain 213 VU-0467154 214 AZ-0108 215 AZ-12201182 216 AZ-27 217 AZ-465 218 AZ-6142 219 AZ-82 220 AZD-3147 221 Drugs for Cardiovascular Diseases 222 HD-001 223 Small Molecule 1 for Malaria 224 Small Molecule to Inhibit 11beta-HSD-1 for Type 2 Diabetes 225 Small Molecule to Inhibit Src Tyrosine Kinase for Lymphangioleiomyomatosis 226 Small Molecules for Diabetic Nephropathy 227 Small Molecules for Tuberculosis 228 Small Molecules to Inhibit Acetohydroxyacid Synthase for Mycobacterium Infections 229 Small Molecules to Inhibit ATP Synthesis for Tuberculosis 230 Small Molecules to Inhibit Carboxypeptidase U for Thrombosis 231 Small Molecules to Inhibit DNA Gyrase B for Tuberculosis 232 Small Molecules to Inhibit DXP-Reductoisomerase for Malaria 233 Small Molecules to Inhibit MALT-1 for Oncology and Autoimmune Disorders 234 Small Molecules to Inhibit p38alpha MAP Kinase for Inflammatory Diseases 235 Small Molecules to Inhibit PLA2 for Undisclosed Indication 236 AstraZeneca Plc - Pipeline Analysis 237 AstraZeneca Plc - Pipeline Products by Target 237 AstraZeneca Plc - Pipeline Products by Route of Administration 246 AstraZeneca Plc - Pipeline Products by Molecule Type 247 AstraZeneca Plc - Pipeline Products by Mechanism of Action 248 AstraZeneca Plc - Recent Pipeline Updates 254 AstraZeneca Plc - Dormant Projects 316 AstraZeneca Plc - Discontinued Pipeline Products 319 Discontinued Pipeline Product Profiles 324 AstraZeneca Plc - Company Statement 344 AstraZeneca Plc - Locations And Subsidiaries 348 Head Office 348 Other Locations & Subsidiaries 348 AstraZeneca Plc - Key Manufacturing Facilities 353 Appendix 354 Methodology 354 Coverage 354 Secondary Research 354 Primary Research 354 Expert Panel Validation 354 Contact Us 354 Disclaimer 355
List of Tables
AstraZeneca Plc, Key Information 22 AstraZeneca Plc, Key Facts 22 AstraZeneca Plc - Pipeline by Indication, 2016 24 AstraZeneca Plc - Pipeline by Stage of Development, 2016 33 AstraZeneca Plc - Monotherapy Products in Pipeline, 2016 34 AstraZeneca Plc - Combination Treatment Modalities in Pipeline, 2016 35 AstraZeneca Plc - Partnered Products in Pipeline, 2016 36 AstraZeneca Plc - Partnered Products/ Combination Treatment Modalities, 2016 37 AstraZeneca Plc - Out-Licensed Products in Pipeline, 2016 39 AstraZeneca Plc - Out-Licensed Products/ Combination Treatment Modalities, 2016 40 AstraZeneca Plc - Pre-Registration, 2016 41 AstraZeneca Plc - Filing rejected/Withdrawn, 2016 42 AstraZeneca Plc - Phase III, 2016 43 AstraZeneca Plc - Phase II, 2016 44 AstraZeneca Plc - Phase I, 2016 46 AstraZeneca Plc - Preclinical, 2016 48 AstraZeneca Plc - Discovery, 2016 51 AstraZeneca Plc - Pipeline by Target, 2016 251 AstraZeneca Plc - Pipeline by Route of Administration, 2016 260 AstraZeneca Plc - Pipeline by Molecule Type, 2016 261 AstraZeneca Plc - Pipeline Products by Mechanism of Action, 2016 262 AstraZeneca Plc - Recent Pipeline Updates, 2016 268 AstraZeneca Plc - Dormant Developmental Projects,2016 330 AstraZeneca Plc - Discontinued Pipeline Products, 2016 333 AstraZeneca Plc, Subsidiaries 362 AstraZeneca Plc, Key Manufacturing Facilities 367
List of Figures
AstraZeneca Plc - Pipeline by Top 10 Indication, 2016 24 AstraZeneca Plc - Pipeline by Stage of Development, 2016 33 AstraZeneca Plc - Monotherapy Products in Pipeline, 2016 34 AstraZeneca Plc - Combination Treatment Modalities in Pipeline, 2016 35 AstraZeneca Plc - Partnered Products in Pipeline, 2016 36 AstraZeneca Plc - Out-Licensed Products in Pipeline, 2016 39 AstraZeneca Plc - Pipeline by Top 10 Target, 2016 251 AstraZeneca Plc - Pipeline by Route of Administration, 2016 260 AstraZeneca Plc - Pipeline by Molecule Type, 2016 261 AstraZeneca Plc - Pipeline Products by Top 10 Mechanism of Action, 2016 262
Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet oRead More...
Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries sRead More...
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from mainRead More...
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.